Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a mean » _ mean (Expand Search)
Showing 1,041 - 1,060 results of 119,701 for search '(( a mean decrease ) OR ( 5 ((step decrease) OR (((we decrease) OR (a decrease)))) ))', query time: 1.53s Refine Results
  1. 1041
    Downregulation of Opa1 and Marf does affect type II NB numbers but affect differentiated cells in lineage.

    Downregulation of Opa1 and Marf does affect type II NB numbers but affect differentiated cells in lineage. by Dnyanesh Dubal (12085942)

    Published 2022
    Save to List
    Saved in:
  2. 1042
    Expression of mRFP does not perturb the severity of <i>opa1</i> RNAi and <i>marf</i> RNAi phenotypes.

    Expression of mRFP does not perturb the severity of <i>opa1</i> RNAi and <i>marf</i> RNAi phenotypes. by Dnyanesh Dubal (12085942)

    Published 2022
    Save to List
    Saved in:
  3. 1043
    Drp1<sup>SD</sup> overexpression in <i>opa1</i> RNAi and <i>marf</i> RNAi expressing type II NB lineages suppresses the differentiation defect.

    Drp1<sup>SD</sup> overexpression in <i>opa1</i> RNAi and <i>marf</i> RNAi expressing type II NB lineages suppresses the differentiation defect. by Dnyanesh Dubal (12085942)

    Published 2022
    Save to List
    Saved in:
  4. 1044
    Flow chart of the expression-based functional screen, with validation steps.

    Flow chart of the expression-based functional screen, with validation steps. by Mohamad Karaky (8910497)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  5. 1045
    Anion-Assisted Glycosylation of Galactose: A Computational Study

    Anion-Assisted Glycosylation of Galactose: A Computational Study by Kerli Tali (22769704)

    Published 2025
    Save to List
    Saved in:
  6. 1046
    Opa1 and Marf depletion leads to fragmented mitochondria and overexpression of Drp1<sup>SD</sup> leads to clustered mitochondria in type II NBs.

    Opa1 and Marf depletion leads to fragmented mitochondria and overexpression of Drp1<sup>SD</sup> leads to clustered mitochondria in type II NBs. by Dnyanesh Dubal (12085942)

    Published 2022
    Save to List
    Saved in:
  7. 1047
    BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells.

    BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells. by Elaine Langenfeld (402034)

    Published 2013
    Save to List
    Saved in:
  8. 1048
    D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis.

    D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis. by Kristine C. McGrath (8269155)

    Published 2020
    Save to List
    Saved in:
  9. 1049
    D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis.

    D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis. by Kristine C. McGrath (8269155)

    Published 2020
    Save to List
    Saved in:
  10. 1050
    Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease

    Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease by Christine M. LaPash Daniels (796881)

    Published 2015
    “…Here we tested whether lithium treatment would decrease levels of GFAP in a mouse model of Alexander disease. …”
    Save to List
    Saved in:
  11. 1051
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 1052
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 1053
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 1054
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 1055
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 1056
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  17. 1057
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  18. 1058
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  19. 1059
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  20. 1060
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:

Search Tools: